World News | Lilly Stays Confident in Possible COVID Drug After Setback

Indianapolis (US), Oct 27 (AP) Eli Lilly continues to back a potential COVID-19 treatment despite research showing that it may not work on hospitalised patients.

The drugmaker on Tuesday said it remains confident that its drug may stop COVID from developing in other patients. Researchers are still studying the drug in mild to moderately ill patients, to try to prevent hospitalisation and severe illness.

Also Read | Anti-France Rally in Bangladesh: Protesters Demand Boycott of French Goods After Emmanuel Macron’s Alleged Islamophobic Comments.

US government officials on Monday said they put an early end to a study testing the antibody drug in hospitalised patients because it doesn't seem to be helping them.

Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated.

Also Read | India, US Can Cooperate on Defeating Wuhan-Originated Virus, Threats from Chinese Communist Party, Says Mike Pompeo.

Lilly shares tumbled in early-morning trading on Tuesday after the company also laid out disappointing third-quarter results.

The drugmaker said its net income fell 4% to $1.21 billion, partly due to $125 in research and development costs for developing potential COVID-19 treatments. Global revenue climbed 5% to $5.74 billion, and adjusted earnings totalled $1.54 per share.

Analysts expected, on average, earnings of $1.71 per share on $5.87 billion in revenue, according to FactSet.

Shares of Indianapolis-based Eli Lilly and Co fell 4% to $136.01 before markets opened. (AP)

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)